MedPath

Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy

Phase 3
Completed
Conditions
Breast Cancer
Interventions
Registration Number
NCT00512993
Lead Sponsor
German Breast Group
Brief Summary

The purpose of this study is to determine the event-free survival (EFS) after zoledronic acid for 5 years versus no postoperative treatment in patients with "chemo-insensitive" breast cancer (ypT1-4 and/or ypN1-3) after preoperative anthracycline/taxane containing chemotherapy

Detailed Description

The study is restricted to patients having had primary systemic chemotherapy for stage II and III breast cancer. Participation in a preoperative chemotherapy trial investigating anthracycline and taxane based regimen is allowed, but not mandatory for all patients. Patients must have significant remaining tumor tissue in the breast and/or axillary lymph node. This implies resistance to further chemotherapy and a clinically relevant risk for relapse. Bisphosphonates have a distinct mechanism of action and have demonstrated efficacy in the treatment of breast cancer with metastasis to the bone as well as adjuvant treatment after surgery of primary breast cancer. The 3rd generation bisphosphonate zoledronic acid has a favorable toxicity profile and can be conveniently given to patients over a long term period.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
654
Inclusion Criteria
  • Written informed consent must be obtained and documented according to the local regulatory requirements prior to beginning specific protocol procedures;
  • Complete baseline documentation sent to GBG;
  • Prior preoperative chemotherapy for at least 4 cycles, of which at least two must contain a taxane and an anthracycline;
  • Completely resected unilateral or bilateral primary carcinoma of the breast with histologically detectable tumor residuals (ypT1-4) and/or histology confirmed involvement of axillary nodes (ypN1-3). Sentinel node biopsy is allowed, but complete axillary clearance is mandatory in node positive cases;
  • A maximum interval of 3 years from date of axillary surgery to entering this trial;
  • Age 18 years or older;
  • Karnofsky index >= 70%;
  • Life expectancy of at least 10 years, disregarding the diagnosis of cancer;
  • No clinical evidence of local recurrence or distant metastases. Complete staging work-up: All patients must have breast ultrasound, chest X-ray, ultrasound or CT scan of the liver within 3 months prior to registration, as well as (bilateral) mammography or breast MRI and bone scan within 8 months prior to registration. In case of a positive bone scan, bone X-ray is mandatory. Other tests may be performed as clinically indicated;
  • Adequate renal and hepatic function (serum creatinine, bilirubin, and transaminases within 1.5 × upper normal range);
  • Patients must be available and compliant for treatment and follow-up. Patients registered on this trial must be treated and followed up at the participating center.
Exclusion Criteria
  • Known hypersensitivity reaction to the investigational compound;
  • Prior postoperative chemotherapy;
  • Prior treatment with bisphosphonates since breast cancer surgery;
  • Pregnant or lactating patients. Patients of childbearing potential must have a negative pregnancy test (urine or serum) within 14 days prior to registration and must implement adequate non-hormonal contraceptive measures (barrier methods, intra uterine contraceptive devices, sterilization) during study treatment;
  • History of diseases with influence on bone metabolism, such as Paget's disease of bone and primary hyperparathyroidism or osteoporosis requiring treatment at the time of study entry or considered likely to become necessary within the six months
  • Other serious illness or medical condition that may interfere with the understanding and giving of informed consent and the conduct of the study
  • Prior or concomitant secondary malignancy (except non-melanomatous skin cancer or carcinoma in situ of the uterine cervix)
  • Concurrent treatment with other experimental drugs or any other anti-cancer therapy;
  • Abnormal renal function as evidenced by a calculated creatinine clearance < 30 ml/minute;
  • Serum calcium concentration < 8.0 mg/dl (2.00 mmol/L) or > 12.0 mg/dl (3.00 mmol/L)
  • Concurrent treatment with sex hormones. Prior treatment must be stopped before study entry;
  • Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw, of exposed bone in the mouth, or of slow healing after dental procedures.
  • Recent (within 6 weeks) or planned dental or jaw surgery (e.g.. extraction, implants)
  • Male patients.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TreatmentZoledronic acidPatients receive zoledronic acid (4mg) for 5 years. Additionally patients receive standard endocrine, radiologic and trastuzumab treatment, respectively
Primary Outcome Measures
NameTimeMethod
The event-free survival (EFS) after zoledronic acid for 5 years versus no postoperative treatment in patients with "chemo-insensitive" breast cancer (ypT1-4 and/or ypN1-3) after preoperative anthracycline/taxane containing chemotherapy.5 years
Secondary Outcome Measures
NameTimeMethod
The bone-metastasis free-survival in both arms.5 years
The overall survival in both treatment arms.5 years
The toxicity of and compliance to zoledronic acid.5 years
The prognostic impact of chemotherapy induced amenorrhea in premenopausal patients.5 years
The EFS with respect to the interval between surgery and randomization.5 years
The predictive value of primary breast tumor response on the effect of postoperative treatment.5 years

Trial Locations

Locations (92)

LKH-Univ. Klinikum Graz, Onkologie

🇦🇹

Graz, Styria, Austria

LKH Salzburg, Uni.klinik f. Innere Med. III/Onkol. Amb.

🇦🇹

Salzburg, Austria

Frauenklinik Rheinfelden

🇩🇪

Rheinfelden, Baden-Württemberg, Germany

Allgemeines Krankenhaus der Stadt Linz, Innere Medizin 3/Zentrum f. Häm. u. Med. Onkologie

🇦🇹

Linz, Upper Austria, Austria

Universitätsklinikum Mannheim, Frauenklinik

🇩🇪

Mannheim, Baden-Württemberg, Germany

Klinikum am Steinenberg

🇩🇪

Reutlingen, Baden-Württemberg, Germany

Landeskrankenhaus Steyr, 2. Med. Abt. Onkologie

🇦🇹

Steyr, Upper Austria, Austria

Landeskrankenhaus Feldkirch

🇦🇹

Rankweil, Vorarlberg, Austria

St. Vincentius Kliniken Karlsruhe

🇩🇪

Karlsruhe, Baden-Württemberg, Germany

Ostalb-Klinikum, ABC Brustzentrum, Frauenklinik

🇩🇪

Aalen, Baden-Württemberg, Germany

Onkol. Schwerpunktpraxis Dr. Knoblich

🇩🇪

Lörrach, Baden-Württemberg, Germany

Krankenhaus Siloah, Gynäkologie und Geburtshilfe

🇩🇪

Pforzheim, Baden-Württemberg, Germany

Praxis Dr. Gottschalk, Fachärztin für Frauenheilkunde und Geburtshilfe

🇩🇪

Bernau, Brandenburg, Germany

Krankenhaus Bad Cannstatt, Frauenklinik

🇩🇪

Stuttgart, Baden-Württemberg, Germany

Universitätsklinikum Tübingen, Frauenklinik

🇩🇪

Tübingen, Baden-Württemberg, Germany

Schwerpunktpraxis der Gynäkologie und Onkologie

🇩🇪

Fuerstenwalde, Brandenburg, Germany

Ruppiner Kliniken, Frauenklinik

🇩🇪

Neuruppin, Brandenburg, Germany

Universität Greifswald, Klinik für Frauenheilkunde und Geburtshilfe

🇩🇪

Greifswald, Mecklenburg-Vorpommern, Germany

Dietrich-Bonhoeffer Klinikum, Frauenklinik

🇩🇪

Neubrandenburg, Mecklenburg-Vorpommern, Germany

Kreiskrankenhaus Ebersberg, Gynäkologisch-onkologische Abteilung

🇩🇪

Ebersberg, Bayern, Germany

Alfried-Krupp-Krankenhaus, Frauenklinik

🇩🇪

Essen, Nordrhein-Westfalen, Germany

Caritas-Krankenhaus St. Josef, Klinik für Frauenheilkunde und Geburtshilfe

🇩🇪

Regensburg, Bayern, Germany

Klinikum Kassel GmbH, Gynäkologische Ambulanz

🇩🇪

Kassel, Hessen, Germany

Vinzenzkrankenhaus, Gynäkologie

🇩🇪

Hannover, Niedersachsen, Germany

Onkologische Schwerpunktpraxis, Dres. Schäfer / Just / Görner

🇩🇪

Bielefeld, Nordrhein-Westfalen, Germany

Gynäkologische Praxis Dr. Deertz

🇩🇪

Essen, Nordrhein-Westfalen, Germany

Uniklinikum, Klinik für Geburtshilfe und Gynäkologie

🇩🇪

Mainz, Rheinland-Pfalz, Germany

Klinikum Stadt Hanau

🇩🇪

Hanau, Hessen, Germany

Klinikum Wels-Grieskirchen GmbH, Abt. f. Innere Medizin IV

🇦🇹

Wels, Upper Austria, Austria

Asklepios Paulinen Klinik, Frauenklinik

🇩🇪

Wiesbaden, Hessen, Germany

Gemeinschaftspraxis Gynäkologie

🇩🇪

Hildesheim, Niedersachsen, Germany

Luisenkrankenhaus, Senologie, Brustzentrum

🇩🇪

Düsseldorf, Nordrhein-Westfalen, Germany

Marienhospital Altenessen

🇩🇪

Essen, Nordrhein-Westfalen, Germany

Medizinische Universität Wien

🇦🇹

Wien, Lower Austria, Austria

Praxis für Innere Medizin, Hämatologie, internistische Onkologie

🇩🇪

Bochum, Nordrhein-Westfalen, Germany

Hermann-Josef Krankenhaus, Frauenklinik

🇩🇪

Erkelenz, Nordrhein-Westfalen, Germany

St. Antonius Hospital, Klinik für Hämatologie u. Onkologie

🇩🇪

Eschweiler, Nordrhein-Westfalen, Germany

Schwerpunktpraxis, Internistisch-gynäkolog.-onkolog.

🇩🇪

Lüneburg, Niedersachsen., Germany

Krankenhaus Cuxhaven, Frauenklinik

🇩🇪

Cuxhaven, Niedersachsen, Germany

SRH Wald-Klinikum Gera gGmbH, Brustzentrum Ostthüringen

🇩🇪

Gera, Thüringen, Germany

Städt. Kliniken Frankfurt-Höchst, Frauenklinik

🇩🇪

Frankfurt/Höchst, Hessen, Germany

St. Markus Krankenhaus, Frauenklinik

🇩🇪

Frankfurt, Hessen, Germany

Klinikum Rosenheim, Abt. Gynäkologie u. Geburtshilfe

🇩🇪

Rosenheim, Bayern, Germany

Schwerpunktpraxis Gynäkologie, Onkologie, Naturheilverfahren

🇩🇪

Berlin-Tempelhof, Berlin, Germany

Intern. Gemeinschaftspraxis

🇩🇪

Friedrichshafen, Germany

GBG Forschungs GmbH

🇩🇪

Neu-Isenburg, Hessen, Germany

Praxisklinik, Krebsheilkunde für Frauen / Brustzentrum

🇩🇪

Berlin, Germany

Universitätsklinikum Erlangen, Frauenklinik mit Poliklinik

🇩🇪

Erlangen, Bayern, Germany

St. Josefs-Hospital, Gynäkologie und Geburtshilfe

🇩🇪

Wiesbaden, Hessen, Germany

Dr.-Horst-Schmidt-Kliniken GmbH, Klinik f. Gyn. und gyn. Onkologie

🇩🇪

Wiesbaden, Hessen, Germany

Henriettenstiftung

🇩🇪

Hannover, Niedersachsen, Germany

Onkologische Schwerpunktpraxis Dr. Glados, Hämatologie / Internistische Onkologie

🇩🇪

Coesfeld, Nordrhein-Westfalen, Germany

Marienhospital Witten, Brustzentrum

🇩🇪

Witten, Nordrhein-Westfalen, Germany

DRK Kliniken Köpenick, Frauenklinik

🇩🇪

Berlin, Germany

Krankenhaus Neunkirchen gGmbH, Frauenklinik

🇩🇪

Neunkirchen, Saarland, Germany

Elisabeth-Hospital, Frauenklinik

🇩🇪

Ibbenbüren, Nordrhein-Westfalen, Germany

St. Vincenz und Elisabeth-Hospital

🇩🇪

Mainz, Rheinland-Pfalz, Germany

Klinikum der Universität zu Köln

🇩🇪

Köln, Nordrhein-Westfalen, Germany

Johanniter-Krankenhaus Genthin-Stendal GmbH, Frauenheilkunde und Geburtshilfe

🇩🇪

Stendal, Sachsen-Anhalt, Germany

Onkologische Schwerpunktpraxis

🇩🇪

Bremen, Germany

Krankenhaus Salzwedel

🇩🇪

Salzwedel, Germany

Klinikum Quedlinburg, Frauenklinik

🇩🇪

Quedlinburg, Sachsen-Anhalt, Germany

Technische Universität Dresden

🇩🇪

Dresden, Sachsen, Germany

Universitätsklinikum, Klinik für Frauenheilkunde und Geburtshilfe

🇩🇪

Jena, Thüringen, Germany

Evangelisches Diakonie-Krankenhaus, Frauenklinik

🇩🇪

Bremen, Germany

A. ö. Krankenhaus der Barmherzigen Brüder, Interne Abteilung

🇦🇹

St. Veit a. d. Glan, Carinthia, Austria

Ostholstein Kliniken GmbH Klinik Oldenburg, Zentrum für Gynäkologie und Geburtshilfe Sana Kliniken Ostholstein

🇩🇪

Oldenburg, Schleswig-Holstein, Germany

Landeskrankenhaus Wolfsberg, Chirurgische Abteilung

🇦🇹

Wolfsberg, Carinthia, Austria

Universitätsklinikum Schleswig-Holstein Campus Kiel

🇩🇪

Kiel, Schleswig-Holstein, Germany

Asklepios-Klinik Lich, Frauenklinik

🇩🇪

Lich, Hessen, Germany

Allgm. Krankenhaus Celle, Frauenklinik

🇩🇪

Celle, Niedersachsen, Germany

Kreiskrankenhaus Gifhorn, Interdisziplinäres Brustzentrum

🇩🇪

Gifhorn, Niedersachsen, Germany

St. Vincenz Krankenhaus, Frauenklinik

🇩🇪

Limburg, Hessen, Germany

Universitätsklinikum, Frauenklinik / Mutter-Kind-Zentrum

🇩🇪

Marburg, Hessen, Germany

Klinikum Schaumburg, Kreiskrankenhaus Stadthagen, Gynäkologie und Geburtshilfe

🇩🇪

Stadhagen, Niedersachsen, Germany

Facharzt für Frauenheilkunde und Geburtshilfe

🇩🇪

Hamburg, Germany

Onkologische Schwerpunktpraxis Dr. Tessen

🇩🇪

Goslar, Niedersachsen, Germany

Klinikum der Otto-v.-Guericke-Universität, Frauenklinik

🇩🇪

Magdeburg, Sachsen-Anhalt, Germany

Krankenhaus St. Elisabeth und St. Barbara Halle, Klinik für Gynäkologie und Geburtshilfe

🇩🇪

Halle / Saale, Sachsen-Anhalt, Germany

Klinikum Chemnitz gGmbH, Frauenklinik

🇩🇪

Chemnitz, Sachsen, Germany

Gemeinschaftspraxis, Fachärzte für Innere Medizin, Hämatologie und Internistische Onkologie

🇩🇪

Dresden, Sachsen, Germany

Onkologie Bethanien, Onkologie / Tagesklinik

🇩🇪

Frankfurt, Hessen, Germany

Asklepios Klinik, Frauenklinik

🇩🇪

Langen, Hessen, Germany

Universitäts Klinikum Innsbruck

🇦🇹

Innsbruck, Tirol, Austria

St. Elisabeth-KKH, Brustzentrum Koeln-Hohenlind

🇩🇪

Köln, Nordrhein-Westfalen, Germany

Kreiskrankenhaus Hameln, Brustzentrum

🇩🇪

Hameln, Niedersachsen, Germany

Klinikum der Universität zu Köln, Klinik und Poliklinik für Gyn. und Geburtshilfe

🇩🇪

Köln, Nordrhein-Westfalen, Germany

Universitätsklinikum Essen, Klinik für Frauenheilkunde und Geburtshilfe

🇩🇪

Essen, Nordrhein-Westfalen, Germany

Marienhospital Herne, Onkologische / Hämatologische Ambulanz

🇩🇪

Herne, Nordrhein-Westfalen, Germany

Klinikum Sindelfingen-Böblingen / Kliniken Böblingen, Frauenklinik

🇩🇪

Böblingen, Baden-Württemberg, Germany

Klinikum Südstadt, Universitätsfrauenklinik

🇩🇪

Rostock, Mecklenburg-Vorpommern, Germany

Universitätsklinikum Schleswig-Holstein

🇩🇪

Lübeck, Schleswig-Holstein, Germany

© Copyright 2025. All Rights Reserved by MedPath